Filing Details

Accession Number:
0000899243-16-012927
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-02-09 17:54:22
Reporting Period:
2016-02-05
Filing Date:
2016-02-09
Accepted Time:
2016-02-09 17:54:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
874716 Idexx Laboratories Inc IDXX In Vitro & In Vivo Diagnostic Substances (2835) 010393723
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1219445 P Brian Mckeon One Idexx Drive
Westbrook ME 04092
Evp, Cfo And Treasurer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-02-05 1,880 $53.19 32,461 No 4 M Direct
Common Stock Acquisiton 2016-02-08 9,054 $17.19 41,515 No 4 M Direct
Common Stock Disposition 2016-02-08 4,200 $69.17 37,315 No 4 S Direct
Common Stock Disposition 2016-02-08 4,854 $70.06 32,461 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Incentive Stock Option (right-to-buy) Disposition 2016-02-05 1,880 $0.00 1,880 $53.19
Common Stock Non-Qualified Stock Option (right-to-buy) Disposition 2016-02-08 9,054 $0.00 9,054 $17.19
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
5,640 2023-12-31 No 4 M Direct
0 2016-02-13 No 4 M Direct
Footnotes
  1. The number of securities reported reflects a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015 (the "Stock Split").
  2. Sale made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  3. Represents the weighted average sales price of the shares sold ranging from a low of $68.73 to a high of $69.73 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  4. Represents the weighted average sales price of the shares sold ranging from a low of $69.76 to a high of $70.33 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  5. This option vests in five equal annual installments, beginning on the first anniversary date (01/01/2015) of the date of grant. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
  6. Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,527 shares on February 14, 2010, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
  7. Not applicable.